Kiora licenses KIO-301 to Théa for up to $301M; $16M upfront, milestones, royalties

KIORA PHARMACEUTICALS INC

$16M upfront; up to $285M in milestones and tiered royalties up to low 20% on net sales.
TOI gets exclusive worldwide rights (ex-Asia) for retinitis pigmentosa and other ophthalmic uses.
Kiora responsible for Phase 2 design; TOI for Phase 3 and commercialization.
Phase 1/2 ABACUS data showed meaningful vision improvements; Phase 2 starts early 2024.
Investor webcast scheduled for Jan 31, 2024 at 5:30 pm ET.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

KIORA PHARMACEUTICALS INC entered into Exclusive License and Development Agreement with Théa Open Innovation SAS valued at up-front payment of $16.0 million (effective 2024-01-25).

Action: entry
Agreement: license
Counterparty: Théa Open Innovation SAS
Value: up-front payment of $16.0 million
Effective: 2024-01-25

Exact text from the filing

On January 25, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Development Agreement (the “Agreement”) with Théa Open Innovation SAS (“TOI”) with respect to the Company’s KIO-301 molecular photoswitch product (the “Product”).

View on SEC.gov

Browse all material agreements →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.